Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ZS-9

- PMLiVE

Early approval for Amgen’s breakthrough leukaemia drug

32% of patients in remission after at least four weeks of Blincyto infusion

- PMLiVE

AZ and Cancer Research UK to collaborate on new medicines

Charity’s scientists to be given access to pharma company’s molecule library

- PMLiVE

BMS’ daclatasvir scuppered by decision to drop companion drug

FDA denies approval due to discontinuation of asunaprevir development

- PMLiVE

FDA adds rare brain infection link to Tecfidera labelling

Biogen Idec’s MS drug gets safety warning

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

Novartis day

FDA needs more time to review Novartis’ cancer drug

Panobinostat is being investigated for use in multiple myeloma

- PMLiVE

Purdue gets FDA nod for abuse-deterrent painkiller

Around 105 people per day die from a drug overdose in the US

- PMLiVE

AZ seeks leg up in antiplatelet market with Brilinta antidote

Reversal agent has been developed by company's biotech subsidiary Medimmune

- PMLiVE

FDA to review Amgen’s cholesterol drug

US regulator accepts first in new class of PCSK9 inhibitors

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

- PMLiVE

Nexium windfall lifts AZ in third quarter

Still to feel effects of generic competition

- PMLiVE

Extra stomach cancer indication for Cyramza in US

FDA backs Lilly drug in combination with paclitaxel chemotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links